Search Results

LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.

BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced a strategic collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health.

ATCC will continue to support the National Cancer Institute’s (NCI) mission to prevent cancer and the Division of Cancer Epidemiology and Genetics (DCEG) Biospecimen Activity and Assay Support (BAAS) program.

LIXTE Biotechnology Holdings, Inc. announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers.

Chimeron Bio, a Philadelphia -headquartered biotech company, has received a 2024 National Institutes of Health’s Small Business Innovation Research Innovative Concept Award through the National Cancer Institute.

LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

PAVmed Inc. announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform™.